Treatment-Resistant Melanoma Genetic Signatures Emerge From Rapid Autopsy Analysis
Source: Genome Web, April 2023
NEW YORK — Researchers have uncovered genetic and gene expression changes in the organs of patients who died of precision treatment-resistant metastatic cutaneous melanoma.
The patients had initially benefited from treatments such as MAPK inhibitors (MAPKi) and immune checkpoint blockade (ICB) but later acquired resistance and succumbed to the disease.
Cutaneous melanoma, a cancer that starts in pigment-producing cells, is among the most metastatic cancers. According to the scientists, who published their results in Nature Medicine on Thursday, previous studies did not focus on the effect of treatments such as MAPKi and ICB on the mutational landscape of the tumors.